CXCL8 and neoplasm: Sanmamed et al. showed serum IL-8 levels to be highly correlated with tumor burden changes in metastatic melanoma and NSCLC patients during treatment with anti-PD-1/anti-CTLA-4 therapy (62, 63), and Yamazaki et al. reported that pretreatment serum IFN-γ, IL-6, and IL-10 levels were significantly higher in those with tumor progression among patients with advanced melanoma given nivolumab (64).